The complex relationship of serum adiponectin to COPD outcomes COPD and adiponectin.
BACKGROUND
COPD is a chronic inflammatory disorder with high risk of cardiovascular morbidity and mortality. Adiponectin is a hormone that has anti inflammatory, antidiabetic, and anti atherogenic activities. We investigated the relationship of serum adiponectin to health outcomes in COPD.


METHODS
We measured adiponectin levels in serum samples from participants of the Lung Health Study, who were smokers with mild to moderate airflow limitation. We determined the relationship of serum adiponectin to hospitalization and mortality using a Cox proportional hazards model and to baseline lung function measurements and bronchial reactivity using multiple regression methods.


RESULTS
Serum adiponectin concentrations were inversely related to hospitalizations and mortality from coronary heart disease (hazard ratio [HR], 0.73; 95% CI, 0.62-0.86) and to cardiovascular disease (HR, 0.83; 95% CI, 0.73-0.94) and positively related to deaths from respiratory causes (HR, 2.09; 95% CI, 1.41-3.11). However, serum adiponectin concentrations were not significantly related to total mortality (HR, 1.10; 95% CI, 0.93-1.29) or cancer-related mortality(HR, 1.11; 95% CI, 0.92-1.34). Serum adiponectin concentrations were significantly related to increased bronchial reactivity and an accelerated decline in lung function (both P , .0001). Smoking status had no material influence on serum adiponectin concentrations.


CONCLUSIONS
Adiponectin is a complex serum biomarker in COPD that is associated with decreased risk of cardiovascular events but increased risk of respiratory mortality. Because serum adiponectin is not significantly influenced by smoking status, it is a very promising biomarker of cardiovascular outcomes in COPD.
University of British Columbia James Hogg Research Center and the Providence Heart and Lung Institute at St. Paul's Hospital, Vancouver, BC, Canada; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea; Department of Medicine, Pulmonary Division, Vancouver, BC, Canada.
Ho Il
HI
Yoon
University of British Columbia James Hogg Research Center and the Providence Heart and Lung Institute at St. Paul's Hospital, Vancouver, BC, Canada.
Yuexin
Y
Li
University of British Columbia James Hogg Research Center and the Providence Heart and Lung Institute at St. Paul's Hospital, Vancouver, BC, Canada.
S F Paul
SFP
Man
University of California at Los Angeles School of Medicine, Los Angeles, CA.
Donald
D
Tashkin
Johns Hopkins University School of Medicine, Baltimore, MD.
Robert A
RA
Wise
University of Minnesota School of Public Health, Minneapolis, MN.
John E
JE
Connett
Department of Medicine, University of Manitoba, Winnipeg, MB, Canada.
Nicholas A
NA
Anthonisen
Department of Pathology, University of British Columbia, Vancouver, BC, Canada.
Andrew
A
Churg
Department of Pathology, University of British Columbia, Vancouver, BC, Canada.
Joanne L
JL
Wright
University of British Columbia James Hogg Research Center and the Providence Heart and Lung Institute at St. Paul's Hospital, Vancouver, BC, Canada. Electronic address: don.Sin@hli.ubc.ca.
Don D
DD
Sin
D052242:Adiponectin / Q000097:blood*; D000328:Adult; D000818:Animals; D015415:Biomarkers / Q000097:blood; D002170:Canada / Q000453:epidemiology; D004195:Disease Models, Animal; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008875:Middle Aged; D016016:Proportional Hazards Models; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood / Q000453:epidemiology* / Q000503:physiopathology; D012129:Respiratory Function Tests; D012307:Risk Factors; D015996:Survival Rate / Q000639:trends; D013997:Time Factors
D052242:Adiponectin; D015415:Biomarkers